July 09, 2026
4 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Adults with major depressive disorder experienced statistically significant and clinically meaningful improvements with a single dose of lysergide through 12 weeks, according to a press release from Definium Therapeutics. “Major depressive disorder and generalized anxiety disorder impose an enormous burden on patients, families and our society,” Robert Barrow, CEO of Definium
July 09, 2026
4 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

People taking Definium Therapeutics' DT120 showed long-lasting reductions in their depression symptoms compared to a placebo, the…

DT120, a psychedelic that activates serotonin receptors, was generally well tolerated, with mostly mild side effects occurring on…

Definium's LSD drug DT120 hit its Phase 3 MDD primary endpoint, beating analyst expectations with significant improvement in…

Definium Therapeutics said that its LSD therapy helped patients with major depression in its first Phase 3 trial, bringing the…

Definium Therapeutics (DFTX) stock hits $38.24 after positive clinical data, but an 84.57 RSI signals the shares are currently…

News and commentary from the psychiatry world